Andrew A. Young简介
AndrewAYoung,ChiefScientificOfficerofIntarciaTherapeutics,Inc,ResearchTrianglePark,NC,USAAndrewYoungreceivedhisMB,ChB(MD)andhisPhDinPhysiologyfromtheUniversityofAuckland,NewZealandFollowingclinicalpracticewiththeAucklandHospitalBoard,andasageneralmedicalpractitioner,hejoinedthefacultyasalecturerintheDepartmentofPhysiologyattheUniversityofAucklandIn1984hebecameaClinicalResearchScientistattheNationalInstitutesofHealthinPhoenix,Arizona,wherehestudiedinsulinresistanceanddiabetesFromthere,hemovedtoBadNauheim,Germany,whereasaMax-PlanckFellowhestudiedtheelectrophysiologyofpainandtemperaturesensationIn1989AndrewYoungjoinedAmylinPharmaceuticalsIncinSanDiegoasthefoundingphysiologist,becomingVicePresident,Researchin1998andasVicePresidentandSeniorResearchFellowin2002Heleadphysiologiccharacterizationofthehormone,amylin,ananalogofwhich,pramlintide,waslaunchedasSYMLIN,afirst-in-classtreatmentforinsulin-requiringdiabetesHewasalsoresponsiblefortheacquisitionandpreclinicaldevelopmentofexenatide,launchedasBYETTA,thefirst-in-classGLP1-mimeticfortreatmentoftype2diabetesHehasconsultedforseveralanti-obesitydevicecompanies,andwasCTO/CMOforone,LeptosBiomedicalIncIn2007,heco-foundedSatiogenPharmaceuticalsInc,aSanDiegostartupfocusinguponlumenally-actingdrugsanddevicesfordiabetesandobesityFromDecember2008untilMarch2015hewasheadofEnteroendocrineBiologyatGlaxoSmithKline,RTP,NC,focusingupontherapiesformetabolicdiseasesIn2015,heco-foundedandwasCSOofPhoundryPharmaceuticalsInc,astartupfocusingupondiscoveryofhigh-potency,peptidase-resistantpeptides,untilPhoundry'sacquisitionbyIntarciaTherapeutics,IncinSeptember2015HeisnowChiefScientificOfficerforIntarcia